Safety of Octocog alfa in severe hemophilia A patients in India
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This study looks at how safe and effective Octocog alfa (a Factor VIII medicine) is for treating sudden bleeds in adults with severe hemophilia A in India. It is for people who already have experience with Factor VIII products and are not on regular preventive treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a male aged 18 or older.
- You have severe hemophilia A (Factor VIII level under 1%).
- You have been treated with Factor VIII concentrates at least 100 times before.
- You are not currently using regular preventative Factor VIII (prophylaxis).
- You and your doctor agree to use Octocog alfa for treating sudden bleeds.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study watches how well damoctocog alfa pegol (a medicine to help blood clot) works in children with hemophilia A. It is for kids ages 7 to 12 who have used factor VIII before and do not have inhibitors (antibodies that stop the medicine from working).
This study tests how well a new factor VIII medicine, efanesoctocog alfa, protects your joints over time. It's for people with moderate or severe hemophilia A who are just starting this treatment.
This study looks at how often people with hemophilia A develop inhibitors (antibodies that block the effectiveness of factor VIII) after using Coageight, a factor VIII replacement therapy. It may help understand the safety of this treatment.
This study tests a new medicine called NXT007 for people with hemophilia A. It compares NXT007 to standard factor VIII treatment to see if it works better at preventing bleeding episodes.
This study checks how well efanesoctocog alfa (a preventive factor VIII treatment) protects your joints over time in people with hemophilia A. It involves regular checkups, joint assessments, and tracking of any bleeding episodes.
This trial tests a new injection called GS1191-0445 for people with hemophilia A. It aims to see if it is safe and works well to prevent or treat bleeding episodes.
Hear when a new Hemophilia A trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.